SHIFT Newsroom · UK
IXCHIQ: UK withdrawal supersedes the 2025 pause
Updated 24 October 2026: the UK authorisation withdrawal announced on 20 October supersedes the older restrictions covered by this archive.
On 20 October 2026, the MHRA announced the withdrawal of IXCHIQ’s UK marketing authorisation following a further safety review. The regulator concluded that its benefits no longer outweigh its risks for UK travellers. Healthcare professionals must no longer prescribe, supply or administer IXCHIQ. MHRA withdrawal notice
This archive originally covered the temporary June 2025 pause for people aged 65 and over. That notice was superseded by tighter restrictions on 11 February 2026. Both earlier positions are now historical: the October withdrawal is the current regulatory decision. Original historical notice
The MHRA says people already vaccinated do not need another vaccination or specific medical treatment because of this decision. Anyone experiencing a suspected side effect should seek medical advice and report it through the Yellow Card scheme. Current MHRA patient advice
This decision concerns IXCHIQ specifically. Travellers should discuss current alternatives and mosquito-bite prevention with a travel-health professional; this article does not assess individual vaccine suitability.
SHIFT’s take
UK authorisation has been withdrawn. The earlier restrictions in this archive must not be used as current eligibility advice.
Known facts
- The MHRA announced the UK authorisation withdrawal on 20 October 2026.
- The older notice records a historical restriction, superseded by subsequent regulatory decisions.